Same Indication

Ponesimod vs Rituximab

Ponesimod vs Rituximab: Overview

This comparison examines the pharmacological differences between Ponesimod and Rituximab.

Mechanism of Action

Rituximab: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

Pharmacokinetics

Half-life: Rituximab β€” 22 days.

Chemical Properties

Type: Ponesimod β€” Small molecule; Rituximab β€” Antibody.